A Phase 2 interventional study of Herpes Zoster Vaccine 1437173A and Placebo vaccine (saline) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-12.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 31st largest by enrollment, is one of 2 that started in 2009, is one of 8 in phase 2, and was the 2nd registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 2 started in 2009.
This study's enrollment of 121 is below the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 31st largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2009, is one of 8 in phase 2, and was the 6th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
The Protocol Posting has been updated following Protocol amendment 2, Sep 2009. The sections impacted are: eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
Biological: Herpes Zoster Vaccine 1437173A
Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
Biological: Herpes Zoster Vaccine 1437173A
Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
Biological: Herpes Zoster Vaccine 1437173A · Biological: Placebo vaccine (saline)
Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
Biological: Placebo vaccine (saline)
Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
1 or 3 doses of Placebo (saline) injected intramuscularly.
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-days (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms \[including nausea, vomiting, diarrhoea and abdominal pain\], temperature \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-days (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Any time during the study up to Day 29 after the last vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (from Day 0 up to Month 15)
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
Time frame: Within the 30-day (Days 0-29) post last vaccination period
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
Time frame: During the entire study period (from Day 0 to Month 15)
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 0
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 1
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 2
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 3
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 4
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Month 4
Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 4
Anti-gE Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 4
Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Months 0, 1, 2, 3, 4 and 15
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Months 0, 1, 2, 3 and 15
Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3, 4 and 15
VZV-specific Mean Antibody Concentrations
Concentrations are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3, 4 and 15
Anti-gE Geometric Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3 and 15
Anti-gE Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3 and 15
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases
A suspected case of HZ could be confirmed by PCR and/or by clinical review of the GSK physician responsible for the study. Rash lesion samples collected from subjects clinically diagnosed as having a suspected case of HZ were tested by by polymerase chain reaction (PCR) using standardized and validated procedures for the laboratory diagnosis of HZ. If the PCR specimen was inadequate or was missing, suspected HZ cases were to be classified as 'a confirmed case of HZ' or 'not a case of HZ' based on the determination by the GSK responsible physician of the study.
Time frame: During the entire study period (from Day 0 to Month 15)
Serological evidence of prior Varicella-Zoster Virus infection for those born in 1980 or later and for those born outside the US before 1980 in a tropical or sub-tropical region was required. All subjects were to have undergone autologous hematopoietic stem cell transplantation (HCT) within the past 50-70 days; and had no additional HCTs planned.
| Milestone | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Started | 30 | 29 | 31 | 30 |
| Completed | 28 | 24 | 23 | 23 |
| Not completed | 2 | 5 | 8 | 7 |
| Withdrew: Serious adverse event | 2 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 2 | 0 |
| Withdrew: Migrated/moved from study area | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 3 |
| Withdrew: Transplant failed/malignancy recurrence | 0 | 1 | 2 | 3 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | GSK 1437173A 2D Group | Placebo 1D Group | Placebo Group |
|---|---|---|---|---|---|
| Any Pain, Dose 1 | 25 | 19 | 22 | 4 | 3 |
| Grade 3 Pain, Dose 1 | 0 | 3 | 1 | 0 | 0 |
| Any Redness, Dose 1 | 2 | 6 | 2 | 1 | 0 |
| Grade 3 Redness, Dose 1 | 0 | 0 | 0 | 0 | 0 |
| Any Swelling, Dose 1 | 1 | 3 | 4 | 0 | 0 |
| Grade 3 Swelling, Dose 1 | 0 | 0 | 0 | 0 | 0 |
| Any Pain, Dose 2 | 24 | 19 | 22 | — | 3 |
| Grade 3 Pain, Dose 2 | 2 | 3 | 1 | — | 0 |
| Any Redness, Dose 2 | 2 | 2 | 7 | — | 1 |
| Grade 3 Redness, Dose 2 | 0 | 0 | 0 | — | 0 |
| Any Swelling, Dose 2 | 1 | 1 | 3 | — | 0 |
| Grade 3 Swelling, Dose 2 | 0 | 0 | 0 | — | 0 |
| Any Pain, Dose 3 | 24 | 15 | — | — | 4 |
| Grade 3 Pain, Dose 3 | 1 | 0 | — | — | 0 |
| Any Redness, Dose 3 | 6 | 4 | — | — | 0 |
| Grade 3 Redness, Dose 3 | 0 | 0 | — | — | 0 |
| Any Swelling, Dose 3 | 4 | 1 | — | — | 0 |
| Grade 3 Swelling, Dose 3 | 0 | 0 | — | — | 0 |
| Any Pain, Across Doses | 27 | 22 | 24 | 4 | 7 |
| Grade 3 Pain, Across Doses | 3 | 5 | 1 | 0 | 0 |
| Any Redness, Across Doses | 6 | 7 | 7 | 1 | 1 |
| Grade 3 Redness, Across Doses | 0 | 0 | 0 | 0 | 0 |
| Any Swelling, Across Doses | 6 | 4 | 4 | 0 | 0 |
| Grade 3 Swelling, Across Doses | 0 | 0 | 0 | 0 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms \[including nausea, vomiting, diarrhoea and abdominal pain\], temperature \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | GSK 1437173A 2D Group | Placebo 1D Group | Placebo Group |
|---|---|---|---|---|---|
| Any Fatigue, Dose 1 | 13 | 11 | 12 | 15 | 7 |
| Grade 3 Fatigue, Dose 1 | 1 | 1 | 0 | 1 | 0 |
| Related Fatigue, Dose 1 | 5 | 7 | 8 | 6 | 1 |
| Any Gastr. sympt., Dose 1 | 6 | 4 | 1 | 9 | 2 |
| Grade 3 Gastr. sympt., Dose 1 | 0 | 0 | 0 | 0 | 0 |
| Related Gastr. sympt., Dose 1 | 3 | 2 | 1 | 3 | 1 |
| Any Headache, Dose 1 | 4 | 1 | 4 | 7 | 2 |
| Grade 3 Headache, Dose 1 | 0 | 0 | 0 | 0 | 0 |
| Related Headache, Dose 1 | 3 | 1 | 4 | 2 | 1 |
| Any Myalgia, Dose 1 | 14 | 12 | 13 | 9 | 3 |
| Grade 3 Myalgia, Dose 1 | 1 | 0 | 1 | 0 | 0 |
| Related Myalgia, Dose 1 | 12 | 9 | 10 | 6 | 2 |
| Any Temperature, Dose 1 | 3 | 3 | 5 | 7 | 1 |
| Grade 3 Temperature, Dose 1 | 0 | 0 | 0 | 2 | 0 |
| Related Temperature, Dose 1 | 3 | 2 | 4 | 5 | 1 |
| Any Fatigue, Dose 2 | 10 | 8 | 16 | — | 8 |
| Grade 3 Fatigue, Dose 2 | 3 | 1 | 1 | — | 0 |
| Related Fatigue, Dose 2 | 7 | 3 | 10 | — | 3 |
| Any Gastr. sympt., Dose 2 | 2 | 2 | 6 | — | 2 |
| Grade 3 Gastr. sympt., Dose 2 | 0 | 0 | 1 | — | 0 |
| Related Gastr. sympt., Dose 2 | 1 | 2 | 2 | — | 0 |
| Any Headache, Dose 2 | 7 | 1 | 6 | — | 2 |
| Grade 3 Headache, Dose 2 | 2 | 0 | 0 | — | 0 |
| Related Headache, Dose 2 | 4 | 0 | 4 | — | 1 |
| Any Myalgia, Dose 2 | 13 | 13 | 19 | — | 5 |
| Grade 3 Myalgia, Dose 2 | 4 | 2 | 1 | — | 0 |
| Related Myalgia, Dose 2 | 12 | 11 | 12 | — | 3 |
| Any Temperature, Dose 2 | 10 | 4 | 4 | — | 1 |
| Grade 3 Temperature, Dose 2 | 0 | 0 | 0 | — | 0 |
| Related Temperature, Dose 2 | 8 | 3 | 4 | — | 0 |
| Any Fatigue, Dose 3 | 15 | 10 | — | — | 8 |
| Grade 3 Fatigue, Dose 3 | 3 | 0 | — | — | 1 |
| Related Fatigue, Dose 3 | 9 | 8 | — | — | 3 |
| Any Gastr. sympt., Dose 3 | 9 | 5 | — | — | 2 |
| Grade 3 Gastr. sympt., Dose 3 | 0 | 0 | — | — | 0 |
| Related Gastr. sympt., Dose 3 | 4 | 3 | — | — | 1 |
| Any Headache, Dose 3 | 12 | 1 | — | — | 4 |
| Grade 3 Headache, Dose 3 | 2 | 0 | — | — | 0 |
| Related Headache, Dose 3 | 9 | 1 | — | — | 3 |
| Any Myalgia, Dose 3 | 18 | 7 | — | — | 5 |
| Grade 3 Myalgia, Dose 3 | 4 | 0 | — | — | 1 |
| Related Myalgia, Dose 3 | 14 | 7 | — | — | 4 |
| Any Temperature, Dose 3 | 6 | 3 | — | — | 2 |
| Grade 3 Temperature, Dose 3 | 1 | 0 | — | — | 0 |
| Related Temperature, Dose 3 | 6 | 3 | — | — | 1 |
| Any Fatigue, Across Doses | 18 | 18 | 20 | 15 | 10 |
| Grade 3 Fatigue, Across Doses | 4 | 2 | 1 | 1 | 1 |
| Related Fatigue, Across Doses | 11 | 11 | 14 | 6 | 5 |
| Any Gastr. sympt., Across Doses | 10 | 7 | 6 | 9 | 4 |
| Grade 3 Gastr. sympt., Across Doses | 0 | 0 | 1 | 0 | 0 |
| Related Gastr. sympt., Across Doses | 7 | 5 | 2 | 3 | 2 |
| Any Headache, Across Doses | 13 | 3 | 9 | 7 | 6 |
| Grade 3 Headache, Across Doses | 3 | 0 | 0 | 0 | 0 |
| Related Headache, Across Doses | 9 | 2 | 7 | 2 | 5 |
| Any Myalgia, Across Doses | 21 | 18 | 22 | 9 | 8 |
| Grade 3 Myalgia, Across Doses | 8 | 2 | 1 | 0 | 1 |
| Related Myalgia, Across Doses | 19 | 15 | 16 | 6 | 5 |
| Any Temperature, Across Doses | 12 | 8 | 8 | 7 | 4 |
| Grade 3 Temperature, Across Doses | 1 | 0 | 0 | 2 | 0 |
| Related Temperature, Across Doses | 10 | 7 | 7 | 5 | 2 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | GSK 1437173A 2D Group | Placebo 1D Group | Placebo Group |
|---|---|---|---|---|---|
| Any AEs | 25 | 23 | 22 | 16 | 21 |
| Grade 3 AEs | 5 | 6 | 2 | 1 | 4 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | GSK 1437173A 2D Group | Placebo 1D Group | Placebo Group |
|---|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 3 | 5 | 2 | 1 | 2 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 6 | 9 | 10 | 8 |
Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 | 0 | 0 | 0 |
Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 | 0 | 0 | 0 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| ALT — Unknown | 0 | 0 | 0 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 28 | 29 | 31 | 29 |
| ALT — Above | 2 | 0 | 0 | 1 |
| AST — Unknown | 0 | 0 | 1 | 1 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 29 | 29 | 29 | 28 |
| AST — Above | 1 | 0 | 1 | 1 |
| BAS — Unknown | 0 | 0 | 0 | 1 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 30 | 29 | 31 | 29 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 0 | 0 | 1 | 1 |
| CAL — Below | 0 | 2 | 1 | 3 |
| CAL — Normal | 30 | 27 | 29 | 26 |
| CAL — Above | 0 | 0 | 0 | 0 |
| CREA — Unknown | 0 | 0 | 0 | 0 |
| CREA — Below | 1 | 0 | 1 | 1 |
| CREA — Normal | 28 | 25 | 27 | 27 |
| CREA — Above | 1 | 4 | 3 | 2 |
| EOS — Unknown | 0 | 0 | 0 | 1 |
| EOS — Below | 5 | 1 | 6 | 6 |
| EOS — Normal | 24 | 28 | 23 | 21 |
| EOS — Above | 1 | 0 | 2 | 2 |
| FIBR — Unknown | 2 | 0 | 1 | 4 |
| FIBR — Below | 3 | 0 | 5 | 0 |
| FIBR — Normal | 25 | 22 | 21 | 24 |
| FIBR — Above | 0 | 7 | 4 | 2 |
| HGB — Unknown | 0 | 0 | 0 | 1 |
| HGB — Below | 22 | 22 | 27 | 23 |
| HGB — Normal | 8 | 7 | 4 | 6 |
| HGB — Above | 0 | 0 | 0 | 0 |
| HCT — Unknown | 0 | 1 | 0 | 1 |
| HCT — Below | 23 | 21 | 27 | 25 |
| HCT — Normal | 7 | 7 | 4 | 4 |
| HCT — Above | 0 | 0 | 0 | 0 |
| LDH — Unknown | 0 | 0 | 1 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 28 | 28 | 29 | 27 |
| LDH — Above | 2 | 1 | 1 | 3 |
| LYM — Unknown | 0 | 0 | 0 | 1 |
| LYM — Below | 11 | 14 | 6 | 9 |
| LYM — Normal | 19 | 15 | 23 | 19 |
| LYM — Above | 0 | 0 | 2 | 1 |
| MON — Unknown | 0 | 0 | 0 | 1 |
| MON — Below | 3 | 4 | 1 | 2 |
| MON — Normal | 27 | 25 | 30 | 27 |
| MON — Above | 0 | 0 | 0 | 0 |
| NEU — Unknown | 0 | 0 | 0 | 1 |
| NEU — Below | 4 | 3 | 7 | 3 |
| NEU — Normal | 26 | 25 | 23 | 26 |
| NEU — Above | 0 | 1 | 1 | 0 |
| PLAT — Unknown | 0 | 0 | 0 | 1 |
| PLAT — Below | 2 | 6 | 6 | 10 |
| PLAT — Normal | 28 | 23 | 25 | 19 |
| PLAT — Above | 0 | 0 | 0 | 0 |
| PT — Unknown | 2 | 0 | 1 | 4 |
| PT — Below | 0 | 0 | 0 | 0 |
| PT — Normal | 27 | 28 | 30 | 25 |
| PT — Above | 1 | 1 | 0 | 1 |
| PTT — Unknown | 2 | 0 | 1 | 4 |
| PTT — Below | 0 | 1 | 0 | 0 |
| PTT — Normal | 27 | 24 | 27 | 22 |
| PTT — Above | 1 | 4 | 3 | 4 |
| RBC — Unknown | 0 | 1 | 0 | 1 |
| RBC — Below | 24 | 25 | 29 | 26 |
| RBC — Normal | 6 | 3 | 2 | 3 |
| RBC — Above | 0 | 0 | 0 | 0 |
| TP — Unknown | 0 | 0 | 0 | 0 |
| TP — Below | 5 | 3 | 8 | 7 |
| TP — Normal | 25 | 26 | 23 | 23 |
| TP — Above | 0 | 0 | 0 | 0 |
| WBC — Unknown | 0 | 0 | 0 | 1 |
| WBC — Below | 9 | 8 | 9 | 6 |
| WBC — Normal | 21 | 20 | 20 | 22 |
| WBC — Above | 0 | 1 | 2 | 1 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| ALT — Unknown | 0 | 0 | 1 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 26 | 28 | 29 | 27 |
| ALT — Above | 4 | 1 | 0 | 3 |
| AST — Unknown | 0 | 0 | 1 | 1 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 25 | 29 | 29 | 27 |
| AST — Above | 5 | 0 | 0 | 2 |
| BAS — Unknown | 0 | 1 | 1 | 0 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 30 | 28 | 29 | 30 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 0 | 0 | 1 | 1 |
| CAL — Below | 1 | 2 | 0 | 1 |
| CAL — Normal | 29 | 26 | 29 | 28 |
| CAL — Above | 0 | 1 | 0 | 0 |
| CREA — Unknown | 0 | 0 | 1 | 0 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 29 | 27 | 26 | 27 |
| CREA — Above | 1 | 2 | 3 | 3 |
| EOS — Unknown | 0 | 1 | 1 | 0 |
| EOS — Below | 7 | 6 | 8 | 7 |
| EOS — Normal | 23 | 22 | 19 | 22 |
| EOS — Above | 0 | 0 | 2 | 1 |
| FIBR — Unknown | 0 | 1 | 0 | 1 |
| FIBR — Below | 3 | 2 | 0 | 5 |
| FIBR — Normal | 24 | 20 | 26 | 22 |
| FIBR — Above | 3 | 6 | 4 | 2 |
| HGB — Unknown | 0 | 1 | 1 | 0 |
| HGB — Below | 19 | 18 | 23 | 25 |
| HGB — Normal | 11 | 10 | 6 | 5 |
| HGB — Above | 0 | 0 | 0 | 0 |
| HCT — Unknown | 0 | 1 | 1 | 0 |
| HCT — Below | 22 | 19 | 24 | 25 |
| HCT — Normal | 8 | 9 | 5 | 5 |
| HCT — Above | 0 | 0 | 0 | 0 |
| LDH — Unknown | 0 | 0 | 1 | 1 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 30 | 28 | 29 | 27 |
| LDH — Above | 0 | 1 | 0 | 2 |
| LYM — Unknown | 0 | 1 | 1 | 0 |
| LYM — Below | 11 | 13 | 8 | 9 |
| LYM — Normal | 19 | 15 | 21 | 21 |
| LYM — Above | 0 | 0 | 0 | 0 |
| MON — Unknown | 0 | 1 | 1 | 0 |
| MON — Below | 8 | 5 | 2 | 5 |
| MON — Normal | 22 | 22 | 27 | 25 |
| MON — Above | 0 | 1 | 0 | 0 |
| NEU — Unknown | 0 | 1 | 1 | 0 |
| NEU — Below | 6 | 9 | 5 | 6 |
| NEU — Normal | 24 | 19 | 24 | 23 |
| NEU — Above | 0 | 0 | 0 | 1 |
| PLAT — Unknown | 0 | 1 | 1 | 1 |
| PLAT — Below | 5 | 4 | 5 | 7 |
| PLAT — Normal | 25 | 24 | 24 | 22 |
| PLAT — Above | 0 | 0 | 0 | 0 |
| PT — Unknown | 0 | 1 | 0 | 1 |
| PT — Below | 0 | 0 | 0 | 0 |
| PT — Normal | 28 | 25 | 29 | 28 |
| PT — Above | 2 | 3 | 1 | 1 |
| PTT — Unknown | 0 | 1 | 0 | 1 |
| PTT — Below | 0 | 1 | 0 | 0 |
| PTT — Normal | 26 | 23 | 26 | 26 |
| PTT — Above | 4 | 4 | 4 | 3 |
| RBC — Unknown | 0 | 1 | 1 | 0 |
| RBC — Below | 24 | 24 | 25 | 29 |
| RBC — Normal | 6 | 4 | 4 | 1 |
| RBC — Above | 0 | 0 | 0 | 0 |
| TP — Unknown | 0 | 0 | 1 | 0 |
| TP — Below | 3 | 2 | 6 | 6 |
| TP — Normal | 27 | 27 | 23 | 24 |
| TP — Above | 0 | 0 | 0 | 0 |
| WBC — Unknown | 0 | 1 | 1 | 0 |
| WBC — Below | 13 | 10 | 8 | 13 |
| WBC — Normal | 17 | 17 | 21 | 16 |
| WBC — Above | 0 | 1 | 0 | 1 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| ALT — Unknown | 1 | 1 | 0 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 26 | 26 | 29 | 24 |
| ALT — Above | 3 | 1 | 0 | 4 |
| AST — Unknown | 1 | 1 | 0 | 0 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 28 | 26 | 29 | 26 |
| AST — Above | 1 | 1 | 0 | 2 |
| BAS — Unknown | 1 | 0 | 0 | 1 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 29 | 28 | 29 | 27 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 1 | 1 | 0 | 0 |
| CAL — Below | 1 | 0 | 0 | 0 |
| CAL — Normal | 27 | 26 | 28 | 27 |
| CAL — Above | 1 | 1 | 1 | 1 |
| CREA — Unknown | 1 | 1 | 0 | 0 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 28 | 25 | 26 | 25 |
| CREA — Above | 1 | 2 | 3 | 3 |
| EOS — Unknown | 1 | 0 | 0 | 1 |
| EOS — Below | 7 | 7 | 5 | 1 |
| EOS — Normal | 21 | 21 | 22 | 25 |
| EOS — Above | 1 | 0 | 2 | 1 |
| FIBR — Unknown | 1 | 1 | 0 | 1 |
| FIBR — Below | 4 | 0 | 4 | 4 |
| FIBR — Normal | 23 | 24 | 23 | 21 |
| FIBR — Above | 2 | 3 | 2 | 2 |
| HGB — Unknown | 1 | 0 | 0 | 1 |
| HGB — Below | 17 | 15 | 20 | 19 |
| HGB — Normal | 12 | 13 | 9 | 8 |
| HGB — Above | 0 | 0 | 0 | 0 |
| HCT — Unknown | 1 | 0 | 0 | 1 |
| HCT — Below | 20 | 18 | 21 | 21 |
| HCT — Normal | 9 | 10 | 8 | 6 |
| HCT — Above | 0 | 0 | 0 | 0 |
| LDH — Unknown | 1 | 1 | 0 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 28 | 24 | 29 | 26 |
| LDH — Above | 1 | 3 | 0 | 2 |
| LYM — Unknown | 1 | 0 | 0 | 1 |
| LYM — Below | 10 | 14 | 4 | 5 |
| LYM — Normal | 19 | 14 | 25 | 22 |
| LYM — Above | 0 | 0 | 0 | 0 |
| MON — Unknown | 1 | 0 | 0 | 1 |
| MON — Below | 4 | 5 | 2 | 5 |
| MON — Normal | 24 | 23 | 27 | 22 |
| MON — Above | 1 | 0 | 0 | 0 |
| NEU — Unknown | 1 | 0 | 0 | 1 |
| NEU — Below | 6 | 4 | 6 | 3 |
| NEU — Normal | 23 | 23 | 23 | 24 |
| NEU — Above | 0 | 1 | 0 | 0 |
| PLAT — Unknown | 1 | 0 | 0 | 1 |
| PLAT — Below | 3 | 4 | 5 | 7 |
| PLAT — Normal | 26 | 24 | 24 | 20 |
| PLAT — Above | 0 | 0 | 0 | 0 |
| PT — Unknown | 1 | 1 | 0 | 1 |
| PT — Below | 0 | 0 | 1 | 0 |
| PT — Normal | 27 | 25 | 28 | 26 |
| PT — Above | 2 | 2 | 0 | 1 |
| PTT — Unknown | 1 | 1 | 0 | 1 |
| PTT — Below | 0 | 0 | 1 | 0 |
| PTT — Normal | 23 | 22 | 24 | 25 |
| PTT — Above | 6 | 5 | 4 | 2 |
| RBC — Unknown | 1 | 0 | 0 | 1 |
| RBC — Below | 22 | 19 | 24 | 22 |
| RBC — Normal | 7 | 9 | 5 | 5 |
| RBC — Above | 0 | 0 | 0 | 0 |
| TP — Unknown | 1 | 1 | 0 | 0 |
| TP — Below | 2 | 1 | 4 | 3 |
| TP — Normal | 27 | 26 | 25 | 25 |
| TP — Above | 0 | 0 | 0 | 0 |
| WBC — Unknown | 1 | 0 | 0 | 1 |
| WBC — Below | 9 | 9 | 7 | 6 |
| WBC — Normal | 20 | 18 | 22 | 21 |
| WBC — Above | 0 | 1 | 0 | 0 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| ALT — Unknown | 0 | 0 | 1 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 25 | 26 | 27 | 27 |
| ALT — Above | 3 | 1 | 0 | 2 |
| AST — Unknown | 0 | 0 | 1 | 0 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 27 | 26 | 27 | 28 |
| AST — Above | 1 | 1 | 0 | 1 |
| BAS — Unknown | 3 | 1 | 0 | 1 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 25 | 26 | 28 | 27 |
| BAS — Above | 0 | 0 | 0 | 1 |
| CAL — Unknown | 0 | 0 | 1 | 0 |
| CAL — Below | 1 | 0 | 0 | 2 |
| CAL — Normal | 27 | 27 | 26 | 26 |
| CAL — Above | 0 | 0 | 1 | 1 |
| CREA — Unknown | 0 | 0 | 1 | 0 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 28 | 25 | 24 | 26 |
| CREA — Above | 0 | 2 | 3 | 3 |
| EOS — Unknown | 3 | 1 | 0 | 1 |
| EOS — Below | 4 | 5 | 4 | 5 |
| EOS — Normal | 20 | 21 | 22 | 20 |
| EOS — Above | 1 | 0 | 2 | 3 |
| FIBR — Unknown | 1 | 0 | 0 | 0 |
| FIBR — Below | 1 | 3 | 3 | 4 |
| FIBR — Normal | 20 | 21 | 21 | 24 |
| FIBR — Above | 6 | 3 | 4 | 1 |
| HGB — Unknown | 3 | 1 | 0 | 1 |
| HGB — Below | 11 | 13 | 14 | 18 |
| HGB — Normal | 14 | 13 | 14 | 10 |
| HGB — Above | 0 | 0 | 0 | 0 |
| HCT — Unknown | 3 | 1 | 0 | 1 |
| HCT — Below | 13 | 15 | 20 | 18 |
| HCT — Normal | 12 | 11 | 8 | 10 |
| HCT — Above | 0 | 0 | 0 | 0 |
| LDH — Unknown | 0 | 0 | 1 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 28 | 27 | 27 | 27 |
| LDH — Above | 0 | 0 | 0 | 2 |
| LYM — Unknown | 3 | 1 | 0 | 1 |
| LYM — Below | 9 | 13 | 7 | 10 |
| LYM — Normal | 16 | 13 | 21 | 18 |
| LYM — Above | 0 | 0 | 0 | 0 |
| MON — Unknown | 3 | 1 | 0 | 1 |
| MON — Below | 2 | 6 | 2 | 5 |
| MON — Normal | 23 | 20 | 26 | 23 |
| MON — Above | 0 | 0 | 0 | 0 |
| NEU — Unknown | 3 | 1 | 0 | 1 |
| NEU — Below | 3 | 3 | 6 | 5 |
| NEU — Normal | 21 | 21 | 22 | 23 |
| NEU — Above | 1 | 2 | 0 | 0 |
| PLAT — Unknown | 3 | 2 | 0 | 1 |
| PLAT — Below | 2 | 3 | 5 | 8 |
| PLAT — Normal | 23 | 22 | 23 | 20 |
| PLAT — Above | 0 | 0 | 0 | 0 |
| PT — Unknown | 1 | 0 | 0 | 0 |
| PT — Below | 0 | 0 | 1 | 0 |
| PT — Normal | 25 | 25 | 27 | 27 |
| PT — Above | 2 | 2 | 0 | 2 |
| PTT — Unknown | 1 | 0 | 0 | 0 |
| PTT — Below | 0 | 0 | 1 | 0 |
| PTT — Normal | 20 | 23 | 22 | 25 |
| PTT — Above | 7 | 4 | 5 | 4 |
| RBC — Unknown | 3 | 1 | 0 | 1 |
| RBC — Below | 15 | 17 | 22 | 24 |
| RBC — Normal | 10 | 9 | 6 | 4 |
| RBC — Above | 0 | 0 | 0 | 0 |
| TP — Unknown | 0 | 0 | 1 | 0 |
| TP — Below | 2 | 3 | 3 | 4 |
| TP — Normal | 26 | 24 | 24 | 24 |
| TP — Above | 0 | 0 | 0 | 1 |
| WBC — Unknown | 3 | 1 | 0 | 1 |
| WBC — Below | 8 | 9 | 7 | 7 |
| WBC — Normal | 16 | 17 | 21 | 21 |
| WBC — Above | 1 | 0 | 0 | 0 |
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| ALT — Unknown | 1 | 0 | 0 | 0 |
| ALT — Below | 0 | 0 | 0 | 0 |
| ALT — Normal | 26 | 26 | 27 | 25 |
| ALT — Above | 2 | 0 | 0 | 1 |
| AST — Unknown | 1 | 1 | 0 | 0 |
| AST — Below | 0 | 0 | 0 | 0 |
| AST — Normal | 28 | 25 | 27 | 24 |
| AST — Above | 0 | 0 | 0 | 2 |
| BAS — Unknown | 1 | 0 | 0 | 0 |
| BAS — Below | 0 | 0 | 0 | 0 |
| BAS — Normal | 28 | 26 | 27 | 26 |
| BAS — Above | 0 | 0 | 0 | 0 |
| CAL — Unknown | 1 | 0 | 0 | 0 |
| CAL — Below | 3 | 0 | 0 | 1 |
| CAL — Normal | 25 | 26 | 27 | 25 |
| CAL — Above | 0 | 0 | 0 | 0 |
| CREA — Unknown | 1 | 0 | 0 | 0 |
| CREA — Below | 0 | 0 | 0 | 0 |
| CREA — Normal | 27 | 23 | 25 | 25 |
| CREA — Above | 1 | 3 | 2 | 1 |
| EOS — Unknown | 1 | 0 | 0 | 0 |
| EOS — Below | 3 | 4 | 3 | 2 |
| EOS — Normal | 24 | 21 | 23 | 22 |
| EOS — Above | 1 | 1 | 1 | 2 |
| FIBR — Unknown | 0 | 1 | 0 | 0 |
| FIBR — Below | 4 | 3 | 2 | 4 |
| FIBR — Normal | 16 | 19 | 22 | 22 |
| FIBR — Above | 9 | 3 | 3 | 0 |
| HGB — Unknown | 0 | 0 | 0 | 0 |
| HGB — Below | 17 | 11 | 14 | 20 |
| HGB — Normal | 12 | 15 | 13 | 6 |
| HGB — Above | 0 | 0 | 0 | 0 |
| HCT — Unknown | 0 | 0 | 0 | 0 |
| HCT — Below | 18 | 14 | 17 | 20 |
| HCT — Normal | 11 | 12 | 10 | 6 |
| HCT — Above | 0 | 0 | 0 | 0 |
| LDH — Unknown | 1 | 1 | 0 | 0 |
| LDH — Below | 0 | 0 | 0 | 0 |
| LDH — Normal | 26 | 24 | 26 | 25 |
| LDH — Above | 2 | 1 | 1 | 1 |
| LYM — Unknown | 1 | 0 | 0 | 0 |
| LYM — Below | 7 | 10 | 9 | 6 |
| LYM — Normal | 21 | 16 | 18 | 19 |
| LYM — Above | 0 | 0 | 0 | 1 |
| MON — Unknown | 1 | 0 | 0 | 0 |
| MON — Below | 6 | 2 | 4 | 5 |
| MON — Normal | 22 | 24 | 23 | 21 |
| MON — Above | 0 | 0 | 0 | 0 |
| NEU — Unknown | 1 | 0 | 0 | 0 |
| NEU — Below | 4 | 2 | 7 | 4 |
| NEU — Normal | 23 | 24 | 20 | 22 |
| NEU — Above | 1 | 0 | 0 | 0 |
| PLAT — Unknown | 0 | 0 | 0 | 0 |
| PLAT — Below | 4 | 5 | 6 | 9 |
| PLAT — Normal | 25 | 21 | 21 | 17 |
| PLAT — Above | 0 | 0 | 0 | 0 |
| PT — Unknown | 0 | 1 | 0 | 0 |
| PT — Below | 0 | 0 | 1 | 0 |
| PT — Normal | 27 | 23 | 26 | 23 |
| PT — Above | 2 | 2 | 0 | 3 |
| PTT — Unknown | 0 | 1 | 0 | 0 |
| PTT — Below | 0 | 0 | 1 | 0 |
| PTT — Normal | 27 | 22 | 20 | 20 |
| PTT — Above | 2 | 3 | 6 | 6 |
| RBC — Unknown | 0 | 0 | 0 | 0 |
| RBC — Below | 21 | 15 | 23 | 23 |
| RBC — Normal | 8 | 11 | 4 | 3 |
| RBC — Above | 0 | 0 | 0 | 0 |
| TP — Unknown | 1 | 0 | 0 | 0 |
| TP — Below | 3 | 1 | 1 | 3 |
| TP — Normal | 25 | 25 | 26 | 23 |
| TP — Above | 0 | 0 | 0 | 0 |
| WBC — Unknown | 1 | 0 | 0 | 0 |
| WBC — Below | 8 | 7 | 8 | 9 |
| WBC — Normal | 19 | 19 | 19 | 16 |
| WBC — Above | 1 | 0 | 0 | 1 |
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
| gE-specific CD4+ T-cells/million T-cells | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | 11963.56 ± 11655.09 | 8114.83 ± 9957.55 | 6974.97 ± 10437.53 | 96.15 ± 108.08 |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations | 29192.9 (11004.7 to 77442.1) | 22503.0 (8432.7 to 60050.2) | 11064.6 (4361.2 to 28071.8) | 406.0 (244.2 to 674.9) |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Anti-gE Mean Antibody Concentrations | 131471.10 ± 169644.69 | 102106.14 ± 116349.94 | 63768.06 ± 100839.95 | 840.46 ± 1119.44 |
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
| VZV specific CD4+ T-cells/million Tcells | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| At Month 0 | 356.11 ± 519.79 | 449.31 ± 637.09 | 343.90 ± 381.20 | 273.91 ± 280.07 |
| At Month 1 | 636.10 ± 886.14 | 1205.59 ± 2680.05 | 303.70 ± 383.32 | 486.97 ± 652.18 |
| At Month 2 | 3818.03 ± 3773.74 | 4466.98 ± 7100.05 | 928.35 ± 1773.80 | 249.91 ± 243.82 |
| At Month 3 | 3488.70 ± 4130.59 | 3628.20 ± 6682.51 | 887.86 ± 1244.78 | 511.33 ± 909.03 |
| At Month 4 | 5359.40 ± 6486.90 | 4243.82 ± 6216.73 | 4481.70 ± 6761.94 | 279.35 ± 246.06 |
| At Month 15 | 3104.65 ± 3543.66 | 3298.68 ± 4326.74 | 2669.66 ± 3121.01 | 320.39 ± 337.72 |
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
| gE-specific CD4+ T-cells/million T-cells | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| At Month 0 | 116.53 ± 180.53 | 145.97 ± 217.01 | 83.15 ± 90.39 | 97.48 ± 148.32 |
| At Month 1 | 856.69 ± 1551.94 | 1376.95 ± 3358.49 | 91.84 ± 118.22 | 133.85 ± 204.90 |
| At Month 2 | 8830.03 ± 9745.11 | 9128.95 ± 12539.86 | 1528.60 ± 3204.39 | 124.53 ± 160.24 |
| At Month 3 | 7111.22 ± 7755.09 | 8415.89 ± 12235.84 | 827.83 ± 1508.97 | 158.13 ± 180.84 |
| At Month 15 | 6865.36 ± 6557.75 | 5900.24 ± 7728.98 | 3859.68 ± 4771.08 | 71.03 ± 80.76 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| At Month 0 | 570.1 (393.1 to 826.8) | 755.1 (479.2 to 1189.9) | 639.9 (397.5 to 1030.1) | 659.2 (496.9 to 874.4) |
| At Month 1 | 922.2 (575.6 to 1477.4) | 1017.3 (609.6 to 1697.7) | 562.4 (346.9 to 912.0) | 729.4 (512.0 to 1039.2) |
| At Month 2 | 4268.5 (2075.7 to 8777.9) | 4541.3 (2506.4 to 8228.2) | 702.4 (398.5 to 1238.0) | 523.5 (351.8 to 779.2) |
| At Month 3 | 3940.7 (1819.0 to 8537.5) | 4598.3 (2292.6 to 9222.8) | 558.2 (302.3 to 1030.6) | 632.7 (374.5 to 1068.8) |
| At Month 4 | 8484.1 (4190.6 to 17176.4) | 6223.4 (2893.7 to 13384.5) | 3196.6 (1532.2 to 6668.9) | 351.9 (207.9 to 595.7) |
| At Month 15 | 1946.5 (1013.4 to 3738.6) | 2598.2 (1327.4 to 5085.6) | 930.3 (390.1 to 2218.6) | 339.4 (159.0 to 724.1) |
Concentrations are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| At Month 0 | 968.22 ± 1466.46 | 1340.29 ± 1685.09 | 1304.22 ± 1866.32 | 843.07 ± 616.78 |
| At Month 1 | 1881.91 ± 2742.85 | 1957.16 ± 2438.00 | 1089.57 ± 1586.68 | 1158.99 ± 1407.26 |
| At Month 2 | 15155.95 ± 22198.03 | 10934.78 ± 13735.35 | 1506.49 ± 2120.19 | 911.09 ± 1211.24 |
| At Month 3 | 13342.90 ± 19278.57 | 12602.99 ± 18030.89 | 1227.40 ± 1794.62 | 2902.89 ± 10461.29 |
| At Month 4 | 23858.74 ± 31173.45 | 16752.32 ± 17738.95 | 10744.24 ± 17397.97 | 753.59 ± 1155.17 |
| At Month 15 | 4694.74 ± 5945.23 | 5482.75 ± 5769.88 | 2956.21 ± 4515.53 | 835.21 ± 947.65 |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| At Month 0 | 531.2 (402.6 to 700.8) | 536.2 (304.0 to 945.7) | 448.0 (289.7 to 692.8) | 659.9 (470.5 to 925.4) |
| At Month 1 | 1489.7 (847.3 to 2619.0) | 1288.1 (684.9 to 2422.5) | 376.1 (239.7 to 590.1) | 619.3 (424.2 to 904.0) |
| At Month 2 | 11963.0 (4739.4 to 30196.6) | 11628.8 (5196.6 to 26022.8) | 1047.8 (564.8 to 1943.9) | 520.2 (349.3 to 774.8) |
| At Month 3 | 13412.9 (4967.1 to 36219.7) | 13385.4 (5506.5 to 32537.7) | 972.6 (520.6 to 1817.2) | 585.2 (310.0 to 1104.9) |
| At Month 15 | 8052.7 (3333.4 to 19453.7) | 9165.5 (3796.0 to 22130.1) | 2968.0 (1184.7 to 7436.1) | 362.3 (170.7 to 768.7) |
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| At Month 0 | 683.78 ± 501.88 | 1366.94 ± 2510.90 | 763.58 ± 818.71 | 1025.07 ± 1177.35 |
| At Month 1 | 4435.62 ± 7776.94 | 3812.19 ± 7197.49 | 675.39 ± 776.37 | 1016.00 ± 1159.33 |
| At Month 2 | 76302.68 ± 118526.31 | 47344.49 ± 78643.10 | 2951.78 ± 4785.22 | 927.04 ± 1221.66 |
| At Month 3 | 88592.39 ± 133279.24 | 62174.90 ± 94796.54 | 2739.11 ± 4458.45 | 8908.62 ± 42086.07 |
| At Month 15 | 42128.75 ± 66869.22 | 30938.91 ± 45130.79 | 16564.63 ± 30523.28 | 1091.74 ± 1585.07 |
A suspected case of HZ could be confirmed by PCR and/or by clinical review of the GSK physician responsible for the study. Rash lesion samples collected from subjects clinically diagnosed as having a suspected case of HZ were tested by by polymerase chain reaction (PCR) using standardized and validated procedures for the laboratory diagnosis of HZ. If the PCR specimen was inadequate or was missing, suspected HZ cases were to be classified as 'a confirmed case of HZ' or 'not a case of HZ' based on the determination by the GSK responsible physician of the study.
| Participants | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | 0 | 2 | 0 | 2 |
Collected over Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6); Unsolicited AEs: during the 30-day post-vaccination period (Days 0-29); SAEs: during the entire study period (Day 0 - Month 15).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK 1437173A F1 Group | 3/30 (10%) | 6/30 (20%) | 29/30 (96.7%) |
| GSK 1437173A F2 Group | 1/29 (3.4%) | 9/29 (31%) | 27/29 (93.1%) |
| Placebo-GSK 1437173A F1 Group | 2/31 (6.5%) | 10/31 (32.3%) | 29/31 (93.5%) |
| Placebo Group | 3/30 (10%) | 8/30 (26.7%) | 21/30 (70%) |
| Event | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/30 | 1/29 | 2/31 | 2/30 |
| PyrexiaGeneral disorders | 0/30 | 0/29 | 2/31 | 0/30 |
| CellulitisInfections and infestations | 0/30 | 0/29 | 2/31 | 0/30 |
| Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/29 | 2/31 | 1/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/30 | 0/29 | 2/31 | 0/30 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/30 | 1/29 | 1/31 | 0/30 |
| PancytopeniaBlood and lymphatic system disorders | 0/30 | 1/29 | 0/31 | 0/30 |
| Clostridial infectionInfections and infestations | 0/30 | 1/29 | 0/31 | 0/30 |
| Clostridium difficile colitisInfections and infestations | 0/30 | 1/29 | 0/31 | 0/30 |
| UrosepsisInfections and infestations | 0/30 | 1/29 | 0/31 | 0/30 |
| Event | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group |
|---|---|---|---|---|
| PainGeneral disorders | 27/30 | 22/29 | 24/31 | 7/30 |
| FatigueGeneral disorders | 18/30 | 18/29 | 25/31 | 10/30 |
| MyalgiaMusculoskeletal and connective tissue disorders | 21/30 | 18/29 | 23/31 | 8/30 |
| HeadacheNervous system disorders | 13/30 | 3/29 | 12/31 | 6/30 |
| PyrexiaGeneral disorders | 12/30 | 9/29 | 12/31 | 4/30 |
| Gastrointestinal disorderGastrointestinal disorders | 10/30 | 7/29 | 11/31 | 4/30 |
| ErythemaSkin and subcutaneous tissue disorders | 6/30 | 7/29 | 7/31 | 1/30 |
| SwellingGeneral disorders | 6/30 | 4/29 | 4/31 | 0/30 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 5/30 | 1/29 | 1/31 | 3/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/30 | 3/29 | 3/31 | 4/30 |
| Age, Continuous(Years) | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 53.1 ± 12.2 | 56.0 ± 11.4 | 57.8 ± 6.8 | 57.3 ± 8.6 | 56.1 ± 10.0 |
| Sex: Female, Male(Participants) | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Female | 12 | 9 | 10 | 11 | 42 |
| Male | 18 | 20 | 21 | 19 | 78 |
| Race/Ethnicity, Customized(Participants) | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Race/Ethnicity — African Heritage/African American | 2 | 2 | 1 | 1 | 6 |
| Race/Ethnicity — American Indian or Alaskan Native | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity — Asian-Central/South Asian Heritage | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity — Asian-East Asian Heritage | 0 | 0 | 0 | 2 | 2 |
| Race/Ethnicity — Asian-Japanese Heritage | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity — Other | 2 | 2 | 0 | 4 | 8 |
| Race/Ethnicity — White-Arabic/North African Heritage | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity — White-Caucasian/European Heritage | 24 | 24 | 30 | 22 | 100 |
Ran from Jul 2009 to primary completion in Apr 2011, 21 months.
Results were first posted in Dec 2017, 6 years 7 months after primary completion. A results delay was requested in Jun 2011.
Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 21 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix